Hunt BioVentures
1900 North Akard Street, Dallas, TX, 75201, United States
Overview
Hunt BioVentures makes investments in young private and public companies with a focus on pharmaceuticals, medical devices and agricultural biotech opportunities. With a start in 2001, Hunt has continually pursued companies with clinical efficacy data or strong human proxy data, which has typically meant companies with products in various stages of clinical trials. Although this later-stage approach will always be core to Hunt’s investment strategy, Hunt will occasionally pursue pre-clinical opportunities, especially those with exceptional management teams. Another important component of the strategy is to invest alongside other experienced life science investors in either a “co-lead” or “follower” manner.
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 0
Investment portfolio
- OvaScience
Participated · Series B · Apr 2012
OvaScience is a fertility company focused on the discovery, development and commercialization of new treatments for infertility. The company is working to improve treatment of female infertility based on patented technology exclusively licensed from Massachusetts General Hospital. Its team of scientists, physicians and advisers includes recognized leaders in the field of reproductive medicine. The company is based in Cambridge, MA. According to a filing with the U.S. Securities and Exchange Commission, OvaScience raised $4M in venture capital. The offering involved 116 separate investors and was transacted with Oppenheimer, Livingston and Leerink Swann acting as brokers. OvaScience is a privately-held fertility company focused on discovering, developing and commercializing novel treatments for infertility. Its approaches are based on egg precursor cell discoveries by co-founder Jonathan Tilly, and the company holds an exclusive license from Massachusetts General Hospital to an issued U.S. patent and related patent applications. OvaScience says it aims to improve the success rates of female fertility treatments and is advancing a pipeline of fertility treatment approaches. The company completed a $37 million Series B financing to support development and commercialization of those approaches. Leadership expects the financing will enable advancement of the pipeline and commercial plans. OvaScience's team of scientists, physicians and advisers are described as recognized leaders in the field of reproductive medicine.
Team
No current team members are available.